Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-08

Clinical Trial Update: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing BI 695501 to adalimumab in active rheumatoid arthritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB (ADALIMUMAB-AATY)
  • BI 695501

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Arthritis, Rheumatoid | Phase 3 | Status: COMPLETED | Results posted: 2017-12-08